Did We Miss The Key Part In The Last NR?I quote"expedite the patient intake to meet our trial goals and lay the groundwork for future trials for other indications," The key part as I see it is that the company now sees potential other indications their patented technology can work for. They will show it is safe/effective in the primary disease and then branching out from there widens the market. Clearly Aspire see the potential here. Carving out that deal with them saves dilution and everything I see from the new management team has been stellar. Including negotiating out of that terrible Asia deal. Cash-on-hand should take them through phase II.